Stingray Therapeutics
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) (NCT06589440) | Stingray Therapeutics | 2024-11-20 |
| A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors (NCT06063681) | Stingray Therapeutics | 2023-10-12 |
Track Stingray Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.